title: Stimulatory mechanism of EM523-induced contractions in postprandial stomach of conscious dogs.
abstract: OBJECTIVE
  EM523, a motilin agonist, is intended to be used as a gastroprokinetic during the postprandial period, but the mechanism(s) by which EM523 stimulates postprandial contractions in the stomach has not been studied before. The aim of this study was to examine the mechanism of contraction-stimulating activity by EM523 in fed dogs.
  
  
  METHODS
  Contractile activity in the gastric antrum of 5 dogs was monitored using a long-term implanted force transducer and measured by integrating the area under the curve. Test materials were continuously infused or injected intravenously.
  
  
  RESULTS
  EM523 (1-30 micrograms/kg) induced a dose-dependent increase in fed-type contractions. EM523-induced contractile activity was partially inhibited by atropine, hexamethonium, dopamine, 5-hydroxytryptamine 3 (5-HT3) receptor antagonist, and substance P antagonist. Atropine-resistant and EM523-induced contractions were further inhibited by 5-HT3 receptor antagonist and substance P antagonist, and the combined use of the two antagonists completely eliminated the atropine-resistant and EM523-induced contractions.
  
  
  CONCLUSIONS
  EM523-induced contractions in the fed stomach are quite different from phase III contractions in the fasted state and are mediated partially through the cholinergic pathway. The noncholinergic pathway involves 5-HT3 and neurokinin 1 receptors.
authors.affiliation: Gastrointestinal Research Laboratories, Gunma University, Maebash, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Shiba
authors.forename: A
authors.initials: A
authors.lastname: Mizumoto
authors.forename: N
authors.initials: N
authors.lastname: Inatomi
authors.forename: N
authors.initials: N
authors.lastname: Haga
authors.forename: O
authors.initials: O
authors.lastname: Yamamoto
authors.forename: Z
authors.initials: Z
authors.lastname: Itoh
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001285:Atropine / Q000494:pharmacology; D004151:Dipeptides / Q000494:pharmacology; D004285:Dogs; D004298:Dopamine / Q000494:pharmacology; D004435:Eating; D004917:Erythromycin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D018738:Hexamethonium / Q000494:pharmacology; D007211:Indoles / Q000494:pharmacology; D009037:Motilin / Q000378:metabolism; D009119:Muscle Contraction / Q000187:drug effects; D009270:Naloxone / Q000494:pharmacology; D017294:Ondansetron / Q000494:pharmacology; D012702:Serotonin Antagonists / Q000494:pharmacology; D013270:Stomach / Q000187:drug effects*; D013373:Substance P / Q000037:antagonists & inhibitors
chemical_list: D000900:Anti-Bacterial Agents; D004151:Dipeptides; D007211:Indoles; D012702:Serotonin Antagonists; C078949:FK 888; D013373:Substance P; D009270:Naloxone; D018738:Hexamethonium; D017294:Ondansetron; D009037:Motilin; D004917:Erythromycin; D001285:Atropine; C061752:EM 523; D004298:Dopamine